The probabilistic sensitivity analyses demonstrated that Andexanet (at its current cost) was cost-effective in 19% of simulations using a willingness-to-pay threshold of $50 000/QALY and 33% of simulations at $150 000/QALY. The strategy of Andexanet had an incremental cost-effectiveness ratio was $219 652 per QALY gained compared with the comparator of PCC. The average discounted lifetime costs were $237 177 Canadian dollars for Andexanet and $177 871 Canadian dollars for PCC. PCC had a discounted life expectancy of 2.09 years and a discounted QALY of 1.28. Andexanet had the highest discounted life expectancy of 2.53 years and a discounted QALY of 1.55. Customer Service and Ordering InformationĪn overall reduction in fatal ICrH and increase in thromboembolic events was associated with Andexanet compared with PCC.
Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA).Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 kommentar(er)
